You can get in touch with Tom by ... The approval comes as two Alzheimer's drugs—lecanemab and donanemab—are already authorized by the FDA. Both are antibody therapies that target amyloid ...

A blood test made by a Malvern company that can help diagnose Alzheimer's disease, a form of dementia affecting more than 7 million Americans, has been cleared by the U.S. Food and Drug ...

The new blood test could help more people determine if they have early-stage Alzheimer’s, so they can get treatment before the disease advances. The U.S. Food and Drug Administration (FDA ...

The earlier Alzheimer’s disease can be diagnosed, the better the outcomes; however, it can be hard to diagnose the disease in its earliest stages. The United States Food and Drug Administration ...

“Specialty neurologists get ... Alzheimer’s may be eligible to receive one of the two amyloid-reducing drugs now on market. Lab-developed blood tests have been used primarily by researchers, or by ...

Leaders of the FDA have published a list of new priorities for the agency. They want to deliver rapidly-approved cures and ...

The European Commission has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, setting it up to become the first amyloid-targeting drug to reach the ...

The U.S. Food and Drug Administration (FDA) approved the first blood test to detect Alzheimer's disease in what federal officials called an "important step" toward diagnosing and treating the ...

Research findings suggest that a new blood test for Alzheimer’s disease has shown promise in accurately identifying people ...

A new blood test that detects a hallmark of Alzheimer's is poised to change the way doctors diagnose and treat the disease. The test, the first of its kind to be cleared by the Food and Drug ...

In a milestone for Alzheimer’s disease diagnosis and care, the U.S. Food and Drug Administration on May 16 cleared for ... Patients and doctors prefer blood tests for routine clinical use. The FDA ...